|
FR2495608A1
(en)
*
|
1980-12-04 |
1982-06-11 |
Morelle Jean |
NEW ASPARTIC ACID DERIVATIVES AND THEIR USES
|
|
SI2319581T1
(en)
|
2004-11-26 |
2015-10-30 |
Ucl Business Plc |
Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
|
|
BRPI1013657A2
(en)
|
2009-04-03 |
2016-04-26 |
Ocera Therapeutics Inc |
phenyl l-ornithine acetate salt production processes, method of compressing phenyl l-ornithine acetate and use of therapeutically effective amount of crystalline form of phenyl l-ornithine acetate salt
|
|
KR20170026672A
(en)
|
2009-06-08 |
2017-03-08 |
유씨엘 비즈니스 피엘씨 |
Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
|
|
KR101888215B1
(en)
|
2010-10-06 |
2018-09-20 |
오세라 테라퓨틱스, 아이엔씨. |
Methods of making l-ornithine phenylacetate
|
|
CN107206021B
(en)
|
2014-11-24 |
2021-09-03 |
Ucl商业有限公司 |
Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapy
|
|
US10835506B2
(en)
|
2015-08-18 |
2020-11-17 |
Ocera Therapeutics, Inc. |
Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
|
|
IL270413B
(en)
|
2017-05-11 |
2022-08-01 |
Ocera Therapeutics Inc |
Processes of making l-ornithine phenylacetate
|
|
CN107540413A
(en)
*
|
2017-09-14 |
2018-01-05 |
精晶药业股份有限公司 |
A kind of method that urea is extracted in the crystalline mother solution from aspartic acid ornithine
|